Cardiovascular drug discovery firm completes $16.6 mil. mezzanine round of financing through private placement of preferred stock. The Mountain View, Calif.-based company initiated its first clinical trial in February for CVT-1, an orally active cholesterol-lowering product designed to inhibit a "cholesterol transport protein that plays a key role in promoting the absorption of cholesterol from the intestine," the firm said. CVT was founded in 1992 and previously raised $13 mil. in two rounds of venture financing
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth